leukemia

by Camryn Haines, Texas A&M University edited by Lisa Lock, reviewed by Andrew Zinin  Editors’ notes  The GIST Add as preferred source The total number of antibiotic administrations among AR-colonization outcome groups. Of the patients who received (A) carbapenem administrations (B) oxazolidinone administrations, and (C) tetracycline administrations, the total administrations of each antibiotic were compared between patients who […]

by Chinese Academy of Sciences edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source A Biomimetic Platform to Enhance CAR T Cell Therapy Against Leukemia. Credit: Li Feng Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen

February 27, 2026 When Chad Mirkin, PhD, asked his graduate students to run a “Friday afternoon experiment” nearly 20 years ago, he wasn’t expecting to affect cancer treatment. He simply wanted to see what would happen if you put spherical nucleic acids (SNAs), a form of DNA he’d invented in 1996, into cell culture. Chad Mirkin,

by Meagan Raeke, Perelman School of Medicine at the University of Pennsylvania edited by Lisa Lock, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Credit: Molecular Cell (2026). DOI: 10.1016/j.molcel.2026.02.003 A new CRISPR-based tool that is directly used on patients’ cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood

by Virginia Tech edited by Sadie Harley, reviewed by Andrew Zinin  Editors’ notes  The GIST Add as preferred source Cancer researchers including senior author Christopher Hourigan (left) and first author Rasha Al-Ali of Virginia Tech’s Fralin Biomedical Research Institute found that a highly sensitive DNA-based test may help doctors predict which patients with acute myeloid leukemia (AML) are

by South Australian Health and Medical Research Institute edited by Lisa Lock, reviewed by Andrew Zinin  Editors’ notes  The GIST Add as preferred source Credit: HemaSphere (2026). DOI: 10.1002/hem3.70291 An Australian research collaboration has led to a major leap forward in the treatment of acute lymphoblastic leukemia (ALL). Recently published clinical trial results have shown evidence that switching part of

by Leslie Orr, University of Rochester Medical Center edited by Lisa Lock, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source TauT loss promotes oxidative stress and MSC senescence. Credit: Cell Death & Disease (2026). DOI: 10.1038/s41419-025-08233-4 In a basic science study last year, researchers discovered that taurine, available in energy drinks and as a supplement, feeds

by Kumamoto University edited by Gaby Clark, reviewed by Robert Egan  Editors’ notes This study shows that TGF-β triggers the nuclear translocation of HBZ specifically in ATL cells from patients with ATL, not in HTLV-1–infected cells from asymptomatic carriers. JunB interacts with HBZ, mediates its translocation, and is crucial for ATL cell survival. The HBZ-JunB complex formation in

by Amy Mone, Valerie Mehl, Johns Hopkins University School of Medicine edited by Lisa Lock, reviewed by Robert Egan  Editors’ notes Precison Therapy for T-Cell Leukemias and Lymphoma. Credit: Suman Paul Lab Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established